Weekly NIH Funding Opportunities and Notices for January 08, 2021

General Notices

- **Notice of NIH Participation in the National Science Foundation Enabling Discovery through GEnomics (EDGE) Program** (NOT-HG-21-014)
  National Human Genome Research Institute

- **NHGRI Notice of Participation in PAR-19-134, "Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)"** (NOT-HG-21-021)
  National Human Genome Research Institute

- **AHRQ Notice of Extension of PA-17-007** (NOT-HS-21-006)
  Agency for Healthcare Research and Quality

- **Findings of Research Misconduct** (NOT-OD-21-047)
  National Institutes of Health

- **Request for Information (RFI): Inviting Comments and Suggestions on the Surgeon-Scientist effort requirement on K08 awards from the National Cancer Institute** (NOT-CA-21-027)
  National Cancer Institute

Notice of Changes to Funding Opportunities

- **Notice to Extend the Expiration Date for PAR-18-580 "Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (UT2 Clinical Trial Optional)"** (NOT-AA-20-026)
  National Institute on Alcohol Abuse and Alcoholism

- **Notice to Update Data Sharing Plan in Section I - Funding Opportunity Description for RFA-FD-21-013 - "Physiologically-based pharmacokinetic (PBPK) models to aid the development of generic dermatological products (U01) Clinical Trials Optional."** (NOT-FD-21-001)
  Food and Drug Administration

- **Notice to Update Data Sharing Plan in Section I - Development of Methods to Evaluate the Impact of Design Differences to the User Interface of Generic Drug-Device Combination Products in Comparison to their Reference Listed Drugs** (NOT-FD-21-002)
  Food and Drug Administration
- Clarification of Scientific Overlap Concerns in PAR-19-367 "Maximizing Investigators’ Research Award (R35 - Clinical Trial Optional)"
  (NOT-GM-21-001)
  National Institute of General Medical Sciences

- Notice of NIMHD Participation in the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) Program
  (NOT-MD-21-010)
  National Institute on Minority Health and Health Disparities

- Notice of NIMHD Participation in PA-21-049 and PA-21-050, Announcements for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowships for Students in Predoctoral Dual-Degree Training Programs (Parent F30)
  (NOT-MD-21-011)
  National Institute on Minority Health and Health Disparities

- Notice to Extend Expiration Date for PAR-19-362: Planning Grant for Global Infectious Disease Research Training Program (D71 - Clinical Trials Not Allowed)
  (NOT-TW-21-001)
  John E. Fogarty International Center

Notices of Special Interest

- Notice of Special Interest: Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)
  (NOT-AA-20-024)
  National Institute on Alcohol Abuse and Alcoholism

- Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
  (NOT-AR-21-012)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

- Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities
  (NOT-CA-21-020)
  National Cancer Institute

- Notice of Special Interest (NOSI): Innovative Molecular Analysis Technologies for Low-Resource Settings Globally
  (NOT-CA-21-025)
  National Cancer Institute

Funding Opportunities

- Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)
  (PAR-21-089)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
- **International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed**  
  (PAR-21-104)  
  John E. Fogarty International Center  
  National Cancer Institute  
  Application Receipt Date(s): March 9, 2021; March 9, 2022; March 8, 2023 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required)**  
  (PAR-21-105)  
  John E. Fogarty International Center  
  National Cancer Institute  
  Application Receipt Date(s): March 9, 2021; March 9, 2022; March 8, 2023 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)**  
  (PAR-21-121)  
  National Center for Advancing Translational Sciences  
  Application Receipt Date(s): See FOA

- **Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)**  
  (PAS-21-031)  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

- **Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)**  
  (RFA-AG-21-033)  
  National Institute on Aging  
  Application Receipt Date(s): March 18, 2021

- **New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)**  
  (RFA-AG-22-006)  
  National Institute on Aging  
  Application Receipt Date(s): See FOA

- **Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed)**  
  (RFA-AI-21-001)  
  National Institute of Allergy and Infectious Diseases  
  Application Receipt Date(s): June 15, 2021. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)**  
  (RFA-DK-20-032)  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt Date(s): June 22, 2021; June 22, 2022; June 22, 2023.
• Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)  
  (RFA-DK-20-508)  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt Date(s): Not Applicable

• Physiologically Based Pharmacokinetic (PBPK) Models of Oral Absorption to Simulate the Results of Bioequivalence Studies (U01) Clinical Trials Optional  
  (RFA-FD-21-012)  
  Food and Drug Administration  
  Application Receipt Date(s): March 15, 2021, by 11:59 PM Eastern Time.

• Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Inhalation Products (U01) Clinical Trials Optional  
  (RFA-FD-21-015)  
  Food and Drug Administration  
  Application Receipt Date(s): March 15, 2021, by 11:59 PM Eastern Time.

• Development of Advanced Analytical Methods for the Characterization of Iron Carbohydrate Complex - Ferric Derisomaltose (U01) Clinical Trials Not Allowed  
  (RFA-FD-21-016)  
  Food and Drug Administration  
  Application Receipt Date(s): March 31, 2021 by 11:59 PM Eastern Time.

• Quantify the expression of metabolizing enzymes and transporter proteins in lung, eye and skin tissue in relevant animal models and humans (U01) Clinical Trial Not Allowed  
  (RFA-FD-21-018)  
  Food and Drug Administration  
  Application Receipt Date(s): March 15, 2021 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

• National Food and Nutrient Analysis Program (U01) Clinical Trial Not Applicable  
  (RFA-FD-21-023)  
  Food and Drug Administration  
  Application Receipt Date(s): March 9, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

• Development of a model selection method for population pharmacokinetics analysis by deep learning based reinforcement learning (U01) Clinical Trials Not Allowed  
  (RFA-FD-21-027)  
  Food and Drug Administration  
  Application Receipt Date(s): March 18, 2021 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)
  (RFA-HL-21-014)
  National Heart, Lung, and Blood Institute
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): See FOA

• Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed)
  (RFA-NS-21-017)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 15, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

• Cellular Senescence Network: Tissue Mapping Centers (U54 Clinical Trial Not Allowed)
  (RFA-RM-21-008)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 08, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Cellular Senescence Network: Technology Development and Application (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-RM-21-009)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 8, 2021

• Cellular Senescence Network: Consortium Organization and Data Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-RM-21-010)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): March 08, 2021